Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 2/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL6195952 | 0.98 | TAAR1 (0.61) | TAAR1SLC6A3IDO1AGXTDRD2 | |
| SCHEMBL5169427 | 0.94 | TAAR1 (0.57) | TAAR1SLC6A3IDO1AGXTDRD2 | |
| SCHEMBL27469018 | 0.89 | TAAR1 (0.52) | TAAR1SLC6A3IDO1AGXTDRD2 | |
| SCHEMBL30728547 | 0.88 | TAAR1 (0.52) | TAAR1SLC6A3AGXTDRD2 | |
| SCHEMBL14041054 | 0.88 | TAAR1 (0.52) | TAAR1SLC6A3AGXTDRD2 | |
| SCHEMBL1056081 | 0.87 | TAAR1 (0.59) | TAAR1SLC6A3IDO1AGXTDRD2 | |
| SCHEMBL3371633 | 0.85 | TAAR1 (0.74) | TAAR1SLC6A3IDO1AGXTDRD2 | |
| SCHEMBL12693653 | 0.85 | LPL (0.61) | TAAR1SLC6A3DRD2SLC6A4 | |
| Ethane SCHEMBL28237447 | 0.85 | TAAR1 (0.57) | TAAR1SLC6A3IDO1AGXTDRD2 | |
| SCHEMBL7178106 | 0.84 | TAAR1 (0.51) | TAAR1SLC6A3IDO1AGXTDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 363 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| WO-2023235548-A1 | SQUARAMIDE DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | RESEARCH TRIANGLE INSTITUTE (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230309388-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2023-09-28 | — | — | US | disclosed |
| WO-2023164118-A1 | BACTERIAL BIOFILM INHIBITORS | THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023164108-A1 | BACTERIAL BIOFILM INHIBITORS | THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023164114-A2 | BACTERIAL BIOFILM INHIBITORS | THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023164115-A2 | BACTERIAL BIOFILM INHIBITORS | THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2006050476-A2 | PYRIMIDINE DERIVATIVES AS ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-05-11 | — | — | WO | disclosed |
| EP-0930296-B2 | FLUORINATED PROSTAGLANDIN DERIVATIVES AND MEDICINES | ASAHI GLASS CO LTD (JP) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004024728-A2 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
| EP-0850926-B1 | Difluoroprostaglandin derivatives and their use | ASAHI GLASS CO LTD (JP) | 2002-10-09 | — | — | EP | disclosed |
| EP-0930296-B1 | FLUORINATED PROSTAGLANDIN DERIVATIVES AND MEDICINES | ASAHI GLASS CO LTD (JP) | 2002-07-24 | — | — | EP | disclosed |
| CN-1246469-A | Naphthacridine derivative and liquid crystal composite containing it | DAINIPPON INK CHEMICAL IND CO (JP) | 2000-03-08 | — | — | CN | disclosed |
| US-5985920-A | COMPOUNDS FOR TREATMENT OF VISION DEFECTS SUCH AS GLAUCOMA | ASAHI GLASS COMPANY LTD. (JP) | 1999-11-16 | — | — | US | disclosed |
| EP-0930296-A1 | FLUORINATED PROSTAGLANDIN DERIVATIVES AND MEDICINES | ASAHI GLASS COMPANY LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
| US-5886035-A | PREVENTIVE AND THERAPEUTICAL MEDICINE FOR EYE DISEASE | ASAHI GLASS COMPANY LTD. (JP) | 1999-03-23 | — | — | US | disclosed |
| EP-0850926-A2 | Difluoroprostaglandin derivatives and their use | ASAHI GLASS COMPANY LTD. (JP) | 1998-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, CYP4F11, WEE1 | TAAR1 4796/4885SLC6A3 4693/4885IDO1 1056/4885 |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | TAAR1 3775/4885SLC6A3 4272/4885IDO1 980/4885 |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | PARP3, PARP1, PARP4 | TAAR1 4878/4885SLC6A3 3804/4885IDO1 2840/4885 |
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | TAAR1 3661/4885SLC6A3 4602/4885IDO1 952/4885 |
| US-20230309388-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE | OCIAD1, OCIAD2, SLCO4C1 | TAAR1 2803/4885SLC6A3 1421/4885IDO1 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.